Gilead to Present 18-Month Anito-cel Trial Follow-Up Data in Multiple Myeloma at ASH 2026

Bitget2026/11/04 14:19

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Gilead Sciences and Kite will present 23 abstracts, including seven oral presentations, at ASH on December 12-15, 2026.
Updated pivotal Phase 2 anito-cel results will assess survival and safety in heavily pretreated patients with relapsed or refractory multiple myeloma.
The anito-cel study supports a U.S. marketing application under FDA review, with a decision target date of December 23, 2026.
Yescarta presentations will include five-year follow-up in first-line high-risk large B-cell lymphoma, alongside real-world treatment outcomes.
Investigational gamgertamig data will provide initial clinical findings on treatment response and durability in relapsed or refractory autoimmune cytopenias.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104303376) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Gilead to Present 18-Month Anito-cel Trial Follow-Up Data in Multiple Myeloma at ASH 2026

You may also like

Crypto prices